Most of these works showed PON1 activities to be decreased in patients with NAFLD/NASH, but, in many cases, the results were inconsistent, leaving many questions rather than clarifying the impact of PON1 in this liver disease. Here, PON1 is linked to metabolic dysfunction-associated steatohepatitis.